Exosomes and the invariant NKT (iNKT) immune cell ligand a-galactosylceramide (aGC) may offer novel tools for cancer immunotherapy. In this study, we investigated whether exosomes loaded with aGC can activate iNKT cells and potentiate a cancer-specific adaptive immune response. aGC loaded exosomes readily activated iNKT cells both in vitro and in vivo. Exosomes loaded with aGC plus the model antigen ovalbumin (OVA) induced potent NK and gd T-cell innate immune responses, and they also synergistically amplified T-and B-cell responses that were OVA specific. In contrast to soluble aGC, which anergizes iNKT cells, we found that aGC/OVA-loaded exosomes did not induce iNKT cell anergy but were more potent than soluble aGC þ OVA in inducing adaptive immune responses. In an OVA-expressing mouse model of melanoma, treatment of tumor-bearing mice with aGC/OVA-loaded exosomes decreased tumor growth, increased antigen-specific CD8 þ T-cell tumor infiltration, and increased median survival, relative to control mice immunized with soluble aGC þ OVA alone. Notably, an additional injection of aGC/OVA-loaded exosomes further augmented the treatment effects. Our findings show that exosomes loaded with protein antigen and aGC will activate adaptive immunity in the absence of triggering iNKT-cell anergy, supporting their application in the design of a broad variety of cancer immunotherapy trials. Cancer Res; 73(13); 3865-76. Ó2013 AACR.
Introduction
Effective antitumor immunity needs activation of both the innate and adaptive immune system to overcome the immune evasion strategies used by tumors. Furthermore, a long-lasting adaptive immune response needs a boost by the innate immune system (1) . Natural killer (NK) cells, cytotoxic CD8 þ T cells, and gd T cells can induce cell death, whereas antibodies are important for antibody-dependent cellular cytotoxicity (ADCC; ref.
2). Thus, effective antitumor therapy needs to activate multiple players of the immune system to mount an effective, multifaceted, and long-lasting immune response (3) . Exosomes are small membrane vesicles around 100 nm, derived from the endosomal compartment and are secreted by many different cell types, among other cancer cells and dendritic cells (4) . They can express immunostimulatory molecules such as MHC molecules, CD80 and CD86 (5) and elicit antigen-specific CD4 þ (6), CD8 þ T cell (7), B-cell responses (8) ,
and NK-cell (9) responses in vivo. Exosomes from melanoma peptide-pulsed dendritic cells were able to reverse tumor growth in mice (7) , which led to the evaluation of exosomes as therapeutic agents and vaccine vehicles (10) . However, two phase I clinical trials using peptide-loaded dendritic cell exosomes in patients with melanoma (11) and non-small cell lung cancer (12) showed that exosomes were well tolerated but had limited immunostimulatory effects. Thus, a better understanding of the exosomal immune response is needed to increase exosomal immunogenicity and thereby improving the chances of therapeutic success. We have recently shown that exosomes induce CD4 þ and CD8 þ T-cell responses in a B cell-dependent manner in vivo (13, 14) where protein loading, but not peptide loading of exosomes enhanced their immunogenicity. We now asked whether dendritic cell-derived exosomes, carrying the lipid antigen-presenting molecule CD1d (15, 16) , can be loaded with glycolipid antigen to activate invariant NKT (iNKT) cells, a T-cell subset that has been shown to be important for anticancer responses (17) and whether this would boost T-and B-cell responses to a protein antigen on the same exosome. iNKT cells are a cell type that share characteristics with both innate and adaptive immune cells (18) , which recognizes self and bacterial glycolipids in a CD1d-dependent manner (19) . Upon activation, iNKT cells rapidly release cytokines such as IFN-g and interleukin (IL)-4 (19) and have impact on subsequent NK-, T-and B-cell responses (20) (21) (22) . Alpha-galactosylceramide (aGC) is a glycolipid that induces a rapid activation of iNKT cells in vivo (19) . However, injection of soluble aGC causes anergy of iNKT cells (23) and multiple injections of aGC in humans have had limited therapeutic effects (24) . Because coupling of aGC-loaded CD1d molecules to antigenic protein or nanoparticles (25) was suggested to overcome anergy induction (26) , we speculated that dendritic cell-derived exosomes could serve as an endogenous delivery platform for protein and glycolipid antigens without inducing anergy.
We report that exosomes loaded with aGC and ovalbumin (OVA) activate iNKT cells, overcome anergy induction, and amplify tumor-specific adaptive immune responses with implications for the development of novel cancer immunotherapy.
Materials and Methods

Mice and antibodies
C57Bl/6, Va14-Ca À/À (kindly donated by Dr. G. Berne, Karolinska Institutet), and CD1d À/À mice (kindly donated by Prof. K. K€ arre, Karolinska Institutet) were bred and maintained under pathogen-free conditions at Karolinska Institutet's animal facility. All experiments were approved by the Stockholm Regional Ethics Committee. A list of antibodies used is available in Supplementary Table S1 .
Bone marrow-derived dendritic cell cultures Bone marrow cells were prepared from female C57Bl/6 or CD1d À/À mice as previously described (13) . On day 6, cells were incubated overnight with 300 mg/mL OVA (grade V; Sigma), 2 mg/mL SIINFEKL (Innovagen), and/or 100 ng/mL aGC (KRN-7000; Larodan Fine Chemicals). On day 7, supernatants were discarded and cells were grown in new medium containing exosome-depleted FCS (27) , GM-CSF, IL-4, and 30 ng/mL LPS (Sigma). On day 9, supernatants were used for exosome preparation.
Exosome preparation Exosomes were prepared as described before (27) , with some modifications. After centrifugation for 30 minutes at 3,000 Â g, supernatants were filtered through a 0.22-mm cutoff filter (Nordic Biosite), pelleted and washed in PBS at 100,000 Â g for 2 hours and 10 minutes. The final pellet was re-suspended in a small volume of PBS and protein content was measured using a DC protein assay according to the manufacturer's instructions (Bio-Rad). Exosomes were aliquoted and frozen at À80 C.
Exosome phenotyping
Sulfate-aldehyde latex microspheres (4 mm; Invitrogen) were coated with anti-CD9 (BDBiosciences) antibodies to enrich for exosomes on the beads as previously described (28) . Exosomes from wt or CD1d À/À mice were coated onto anti-CD9 latex beads at a ratio of 50 mg protein per mL beads and phenotyped as described before (13) using specific antibodies and corresponding isotype controls (Supplementary  Table S1 ). Data were acquired using a FACSCalibur (BDBiosciences) and analysis was done using FlowJo software (Tree Star Inc.).
In vitro proliferation A total of 7.5 Â 10 5 splenocytes were labeled with 5 mmol/L carboxyfluorescein succinimidyl ester (CFSE; Invitrogen) and stimulated with exosomes at different concentrations (0.05, 0.5, 5, and 50 mg/mL) for 72 hours. DimerX (BD Biosciences) was loaded overnight with sonicated aGC at 37 C and labeled with antimouse IgG 1 Alexa 647 (Invitrogen). To stain for iNKT cells, cells were F c -blocked (BDBiosciences), incubated with Live/Dead viability marker (Invitrogen), DimerX, and antibodies against B220, CD4, NK1.1, T-cell receptor b chain (TCR-b; all Biolegend). Data were acquired using a FACSAria (BDBiosciences).
In vivo proliferation
C57Bl/6 wild-type mice (wt) or CD1d À/À female mice were injected on day 0 or on days 0 and 14 i.v. with soluble aGC, soluble OVA, or 40 mg of exosomes from wt or CD1d
À/À dendritic cells. Mice were fed with 0.8 mg/mL 5-bromo-2 0 -deoxyuridine (BrdU; Sigma) in drinking water either for 7 days or in intervals from day 0 to 1, day 1 to 3, day 3 to 5, or day 5 to 7. Mice were sacrificed on days 1, 3, 5, 7, or 21 and blood, liver, and spleen were removed. Hepatic lymphocyte preparations and splenocyte single-cell suspensions were prepared as described previously (13, 29) and serum was prepared from coagulated blood and frozen at À20 C. BrdU incorporation was measured using a BrdU staining kit (BDBiosciences), according to the manufacturer's instructions. For OVA-specific CD8 þ T-cell staining, cells were incubated with phycoerythrin (PE)-labeled H-2K b /SIINFEKL pentamer (ProImmune). Data were acquired using FACSAria (BDBiosciences).
B16/OVA melanoma tumor model
A total of 1 Â 10 5 B16/OVA melanoma cells were injected s.c. in the right flank of C57Bl/6 mice. Mice were treated i.v. either with PBS or with 40 mg of exosomes 11 days after tumor injection, when tumors were palpable, or on day 4, or on day 4 and 11 as indicated in figure legends. Tumor growth was monitored regularly and mice were euthanized when tumors reached 1,000 mm 3 in size. Tumors were removed, and either embedded in Killik (Bio-Optica) and frozen at À80 C for immunohistochemistry or homogenized for FACS analysis using antibodies against CD45, B220, TCRb, CD8 (Supplementary Table S1 ) and PE-labeled H-2K b / SIINFEKL pentamer (ProImmune).
Tumor immunohistochemistry
Eight-micrometer sections of Killik-embedded tumors were fixed in acetone, dried overnight, and blocked with goat serum, avidin, and biotin (Vector Laboratories). Samples were stained with anti-TCR-b-APC and analyzed using a Leica DM IRBE microscope.
Intracellular cytokine staining
Splenocytes were restimulated ex vivo for 4 hours using 50 ng/mL Phorbol 12-myristate 13-acetate (PMA), 500 ng/mL ionomycin, and 1 mg/mL Brefeldin A (all from Sigma) as previously described (30) .
ELISPOT
Enzyme-linked immunospot assay (ELISPOT) for IFN-g was done according to the manufacturer's instructions (Mabtech) using 200,000 splenocytes per well. Splenocytes from Va14-transgenic mice were stimulated with a serial dilution of soluble aGC or 0.05, 0.5, 5, and 50 mg/mL of exosomes for 72 hours. Splenocytes were stimulated in vitro with 2 mg/mL aGC, 2 mg/mL SIINFEKL, 2 mg/mL OVA 323-339 peptide (Innovagen), 2 mg/mL Concanavalin A (Sigma), or left unstimulated for 22 hours.
ELISA
IFN-g and IL-17A concentrations were determined in serum or in supernatants from ELISPOT experiments using ELISA according to the manufacturer's instructions (Mabtech). Mouse sera from in vivo experiments were analyzed for concentrations of OVA-specific IgG, total IgG, IgG 2c , and IgG 1 as described before (13) .
Statistical analysis
Student t test or one-way ANOVA with Bonferroni's correction was used for normally distributed data. Mann-Whitney or Kruskal-Wallis with Dunn's correction was used for nonparametric data. For kinetic experiments, 2-way ANOVA with Bonferroni's correction was used. Statistical analysis was conducted using GraphPad software (GraphPad Inc.).
Results
Dendritic cell-derived exosomes express CD1d and induce iNKT-cell activation in vitro
To confirm that exosomes from bone marrow-derived dendritic cells express CD1d (16) , exosomes from C57Bl/6 wt or CD1d À/À dendritic cells were generated and phenotyped using anti-CD9-coated latex beads and flow cytometry. Both wt and CD1d À/À exosomes expressed similar amounts of MHC class II (I-A /I-E ), CD9, CD11c, CD40, CD54, CD80, CD81, and CD86, but only exosomes from wt dendritic cells expressed CD1d (P ¼ 0.004; Fig. 1A) .
Next, we investigated whether exosomes loaded with aGC could activate iNKT cells in vitro. OVA-loaded (Exo-OVA) or aGC-loaded exosomes (Exo-aGC) from wt mice or Exo-aGC from CD1d
À/À mice (CD1d À/À Exo-aGC) were added to splenocytes from Va14 mice, transgenic for the iNKT cell receptor. Exo-aGC induced proliferation in the majority of iNKT cells whereas CD1d À/À Exo-aGC induced substantially less iNKT cell proliferation and Exo-OVA induced none ( Fig. 1B and C) shown by CFSE dilution assay. Exo-aGC also induced increased numbers of IL-4-producing splenocytes as determined by ELISPOT (Fig. 1D ) and higher levels of IFN-g and IL-17A using ELISA than did CD1d À/À Exo-aGC and Exo-OVA ( Fig. 1E and F) . However, CD1d À/À Exo-aGC induced higher cytokine responses than Exo-OVA ( Fig. 1D-F Fig. 2A and B) . iNKT cells upregulated the activation marker CD69 on day 1 (Fig. 2C ) and proliferated up to day 5 ( Fig. 2D ) in response to Exo(aGC-OVA), but not to Exo-OVA or PBS. Hepatic iNKT cells showed similar patterns of activation and proliferation as their splenic counterparts (data not shown). Intracellular cytokine staining showed that splenic iNKT cells produce IFN-g during the first 5 days (Fig. 2E ), whereas IL-4 was produced during the first 3 days (Fig. 2F ) in response to Exo(aGC-OVA) but not to PBS or Exo-OVA.
As reported by others (20, 31) , activation of iNKT cells led to an early activation and proliferation of dendritic cells, NK, and gd T cells, the latter two being innate-like lymphocytes with important functions in anticancer immunity ( Supplementary  Fig. S1 , data not shown). Interestingly, we also detected significantly lower levels of the complement receptor CD21 on marginal zone B (MZB) cells on day 1 after Exo(aGC-OVA) injection and increased proliferation between days 1 and 3 in comparison to Exo-OVA immunization (Supplementary Fig.  S2A and S2B). These data indicate that aGC-loaded exosomes induce an early iNKT-cell response, dendritic cell, MZB cell activation as well as NK-and gd T-cell activation and proliferation in vivo.
Exosomes loaded with aGC potentiate OVA-specific CD8 þ T-cell responses CD8 þ T cells are adaptive immune cells that are crucial for exosome-induced antitumor immunity (7). We detected that Exo(aGC-OVA) stimulated OVA-specific CD8 þ T-cell proliferation and led to a larger pool of OVA-specific CD8 þ T cells, 7 days after exosome injection in comparison to PBS and Exo-OVA-immunized groups ( Fig. 3A-C ). This effect was not due to an aGC-induced polyclonal CD8 þ T-cell expansion because Exo(aGC-SIINFEKL) immunized mice did not have increased numbers of OVA-specific CD8 þ T cells (Fig.   3B ). This is in agreement with previous data where SIINFEKL peptide-loaded exosomes are not sufficient to stimulate proliferation of OVA-specific CD8 þ T cells in vivo, because B-cell activation is needed for exosome-induced T-cell activation in vivo (14) . The increase in OVA-specific CD8 þ T cells was iNKT cell dependent ( Fig. 3C ). Proliferation of OVAspecific CD8 þ T cells was detected on days 5 and 7 in Exo (aGC-OVA)-immunized mice ( Fig. 3D ), leading to a significantly increased OVA-specific CD8 þ T-cell pool on days 5 and 7 when compared with PBS and Exo-OVA (Fig. 3E ). Similar kinetics for OVA-specific CD8 þ T cells were observed in the liver (data not shown). Exo(aGC-OVA) immunization generated increased numbers of SIINFEKL-specific IFN-g producing cells as detected by ELISPOT (Fig. 3F ), an effect that was dependent on exosomal CD1d (Fig. 3G ). These results show that aGC-loaded exosomes amplify antigenspecific CD8 þ T-cell responses via iNKT cells in vivo and that exosomal CD1d has an important role in that response.
aGC-loaded exosomes boost CD4 þ T-and B-cell responses Antibodies are crucial in initiating ADCC, which is an important mechanism in antitumor immunity. Thus, we investigated the effect of aGC-loaded exosomes on T-helper cell responses and humoral immunity. We observed that proliferation of CD4 þ T cells was significantly increased in the spleen in response to Exo(aGC-OVA) compared with PBS and Exo-OVA 7 days after exosome injection ( Two-way ANOVA was used to test for statistical significance. Bars indicate mean þ SEM. Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001.
was iNKT cell-dependent because responses were lower in CD1d À/À mice (Fig. 4B) . Injection of Exo(aGC-OVA) also induced proliferation of follicular helper T cells (Tfh-cells; Supplementary Fig. S3 ), which are important for antibody class switching. In line with this, we detected increased numbers of total and proliferated germinal center B cells and plasma cells ( Supplementary Fig. S4B-S4G ), but not of follicular B cells ( Supplementary Fig. S4A ), and OVA-specific IgG levels were significantly higher already 7 days after immunization with Exo(aGC-OVA) when compared with all other groups (Fig. 4C) . Intriguingly, only the Th1 antibody subclass IgG 2c , but not IgG 1 or total IgG antibodies, were significantly increased in serum of Exo(aGC-OVA)-treated mice compared with both PBS and Exo-OVA (Fig. 4D) . Thus, Exo(aGC-OVA) induce CD4 þ T-cell activation and increased B-cell responses, possibly via the induction of T-follicular helper cells and germinal center formation.
Antigen-loaded exosomes are more potent than soluble antigens in inducing adaptive immunity It has been suggested that codelivery of aGC together with a protein antigen to the same APC is important to potentiate adaptive immune responses (32) . To compare the efficiency of exosome-bound aGC and soluble aGC as adjuvant, we estimated the OVA and aGC content on Exo(aGC-OVA), using IFN-g ELISPOT and ELISA ( Fig. 5A and B) . We injected 40 mg of Exo(aGC-OVA) or the equivalent amount of soluble OVA (range: 32-320 ng) and aGC (range: 22-200 ng) and measured proliferation of innate and adaptive immune cells. Importantly, Exo(aGC-OVA) were less potent in inducing iNKT-and NK-cell proliferation compared with soluble aGC and OVA, whereas the opposite was true for gd T cells, CD4 þ T cells, and OVA-specific CD8 þ T cells (Fig. 5C) . After a second injection, we also observed stronger B-cell responses with significantly higher numbers of GC B cells and OVAspecific IgG levels in exosome-treated mice (Fig. 5D ). These findings show that aGC is a more effective adjuvant for adaptive immune responses when loaded to exosomes compared to soluble ligand.
Exo(aGC-OVA) does not induce iNKT-cell anergy Soluble aGC induces iNKT-cell anergy already after 1 injection, a possible reason for the limited clinical success of aGCbased immunotherapies (23, 25) . To test whether aGC-loaded exosomes were less prone to induce iNKT-cell anergy, we injected PBS, soluble aGC þ OVA, or Exo(aGC-OVA) 2 times with 2-week interval (Fig. 6A) and measured serum IFN-g, iNKT-cell proliferation, and IFN-g production in ELISPOT to determine anergy induction. As expected, soluble aGC and OVA induced significantly higher levels of serum IFN-g after the first injection when compared with both PBS and Exo (aGC-OVA) groups. However, only Exo(aGC-OVA) induced increased levels of serum IFN-g after both injections (Fig. 6B) . After boosting, iNKT cells from soluble aGC þ OVA, but not from Exo(aGC-OVA)-injected mice had decreased CD69 expression (Fig. 6C ) and were refractory to ex vivo restimulation with aGC (Fig. 6D) . Accordingly, we detected significantly more IFN-g producing OVA-specific CD8 þ T cells in splenocytes from twice exosome-injected mice (Fig. 6D) . These results indicate that aGC-loaded exosomes can stimulate IFN-g secretion by iNKT cells even after a second injection, in contrast to soluble aGC, and strikingly, boost adaptive immune responses.
Exo(aGC-OVA) decrease tumor growth and induce T-cell infiltration in a mouse melanoma model
Having shown that exosomes codelivering glycolipid and protein antigen potentiate adaptive immune responses without inducing iNKT-cell anergy, we investigated the potency of Exo(aGC-OVA) to improve antitumor immunity. We injected mice with OVA-expressing B16 melanoma cells and treated on day 4 and/or 11 with PBS, Exo-OVA, soluble aGC þ OVA, or Exo(aGC-OVA). Tumor bearing mice receiving 1 (day 4 or day 11) or 2 (day 4 and 11) injections of Exo(aGC-OVA) had a significantly increased median survival compared with PBS, Exo-OVA, and soluble aGC þ OVA groups ( Fig. 7A and B ; Supplementary Fig. S5A and S5B) . Moreover, 2 injections of Exo (aGC-OVA) significantly prolonged survival while slowing down tumor growth when compared with 1 injection of exosomes ( Fig. 7A and B) . Using flow cytometry and immunofluorescence, we observed more tumor T-cell infiltrates and detected higher levels of OVA-specific CD8 þ T cells in tumor tissues ( Fig. 7C; Supplementary Fig. S5C ). Similarly, OVAspecific IgG levels in serum of Exo(aGC-OVA)-treated mice compared with Exo-OVA or PBS-treated mice were significantly elevated ( Fig. 7D; Supplementary Fig. S5D ). Together these results show that Exo(aGC-OVA) but not soluble aGC þ OVA induce tumor-specific B-and T-cell responses that lead to potent antitumor immunity and that treatment effects can be amplified by 2 injections of Exo(aGC-OVA).
Discussion
We show in this study that aGC-loaded exosomes can induce iNKT-cell activation in vitro and in vivo, without inducing iNKT-cell anergy, leading to enhanced adaptive immune responses and increased antitumor immunity. Importantly, only aGC codelivered with a protein antigen on exosomes boosted adaptive immune responses and could activate iNKT cells upon a second injection. These are important findings to consider when designing future cancer immunotherapy.
Exosomes from wt BMDC loaded with aGC induced stronger iNKT-cell proliferation and proinflammatory cytokine production than exosomes from CD1d perhaps on uptake receptors such as LDL receptors (33). We and others reported previously that whole protein antigens can be retained on exosomes after dendritic cell pulsing (8, 13, 14) and lipid antigens might be retained on exosomes in a similar fashion. Alternatively, the aGC not loaded on CD1d could be located within the exosome. However, the mechanism of how externally added antigen is retained in membrane vesicles remains a matter of investigation. In this study, we confirmed our recent finding that B-cell activation is needed for a potent CD8 þ T-cell activation in vivo (14) . Here, aGC loading of exosomes was not able to overcome the inability of peptide-loaded exosomes to induce antigenspecific CD8 þ T-cell responses. We speculate that the adjuvant properties of aGC cannot compensate for the need of CD4 T-cell activation (36) and our recent data suggest that also B cells, including MZB cells, have a role in exosome-induced immune responses (14, 37) . It is possible that, similar to immune complexes (38) , MZB-cell transport exosomal cargo into splenic B-cell follicles. Interestingly, C3 fragments have been found in proteomic analyses of dendritic cell-derived exosomes preparations (39) . Thus, we speculate that exosome transport by MZB cells allows for B-cell activation, whereas dendritic cell transport of exosomes into the T-cell zone allows for T-cell activation and that both mechanisms are crucial for potent exosome-mediated immune effects. Exosomes also induced NK-and gd-cell proliferation and IFN-g production in an iNKT-cell-dependent manner. gd T cells express NKG2D, which can bind to ligand-expressing tumor cells (40) and due to their cytotoxic properties have been attributed important functions in melanoma immunity (41) . In our study, proliferation and cytokine kinetics were similar for NK-and gd T-cell activation by aGC-loaded exosomes. Although NK cells were also efficiently activated by soluble aGC, gd T cells were not. In contrast, a recent report showed that a high dose of soluble aGC can induce gd T-cell activation (42) . These differences might be due to exosomes lowering the threshold for aGC-induced gd T cell activation by synergistically providing additional activation signals, such as NKG2D ligands (9) . In the same study, gd T-cell activation also led to an increased CD8 þ T-cell response (42) , indicating that the aGC-induced innate immune response is needed for effective adaptive immunity to develop. Following the innate immune response, we observed proliferation of OVA-specific, IFN-g-producing CD8
þ T cells after injection with Exo(aGC-OVA), an effect that was superior to that of exosomes lacking aGC. It has recently been shown that aGC-activated iNKT cells can induce CD8a þ dendritic cells to produce CCL-17, a CCR4 ligand that led to increased CD8 þ Tcell recruitment to the activated dendritic cell (32) . This suggests an important role for codelivery of protein and glycolipid antigen to the same dendritic cell and is in accordance with the iNKT-cell-dependent increase in antigen-specific CD8 þ T-cell numbers we detect after Exo(aGC-OVA) immunization. The cross-talk between iNKT cells and dendritic cells then allows for a selective recruitment of CD8 þ T cells to activated, protein antigen-presenting dendritic cells. 
The CD8
þ T-cell response was accompanied by proliferation of T-helper cells and production of OVA-specific antibodies. Interestingly, we found that T follicular helper cells, important in germinal center formation, were proliferating 5 days after Exo(aGC-OVA) injection, preceding an increase in numbers of germinal center B cells and plasma cells on day 7. In accordance with this, a second injection of Exo(aGC-OVA) led to higher numbers of GC B cells and boosted OVA-specific IgG. We speculate that Exo(aGC-OVA) induces the formation of Tfh cells, which leads to subsequent formation of germinal centers in which germinal center B cells undergo affinity maturation, somatic hypermutation, and differentiate into plasma cells that produce antigen-specific antibodies. We found that Exo(aGC-OVA) predominantly induced IgG 2c antibodies, indicative of a Th1 immune response. In accordance, two studies have previously reported that exosomes induce Th1 immunity (8, 13) . The production of IFN-g during the early phase of the immune responses by iNKT, NK, and gd T cells might lead to the Th1-biased ensuing adaptive immune response. An exciting finding is that aGC-loaded exosomes, in contrast to soluble aGC, do not induce iNKT-cell anergy 
OVA-Pentamer
2 × Exo(αGC-OVA) Figure 7 . Exo(aGC-OVA) but not soluble aGC and OVA reduces tumor growth, increases survival, and induces adaptive antitumor immunity in a mouse melanoma model. C57Bl/6 mice were injected s.c. with 1 Â 10 5 B16/OVA melanoma cells. Tumor growth was monitored regularly and mice were treated on day 4 (PBS, 1 Â Exo(aGC-OVA) and 1 Â aGC þ OVA) or on days 4 and 11 (2 Â Exo(aGC-OVA) and 2 Â aGC þ OVA). Mice were euthanized when tumors reached 1,000 mm 3 in volume. A and B, Kaplan-Meier survival curve ( A) and tumor size (B) for all 5 groups. Dots represent mean À SEM. Mantel-Cox test with Bonferroni multiple test adjustment was used to test for significance in A and 2-way ANOVA was used to test for statistical significance in B. Ã , P < 0.05; ÃÃ , P < 0.01. C, representative dot plots of flow cytometry and quantitation of OVA-specific CD8 þ T-cell infiltration (defined as CD45 correction was used to test for statistical significance. Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001. D, OVA-specific IgG levels in sera of euthanized mice as determined by ELISA. Dots represent mean AE SEM. Two-way ANOVA was used to test for statistical significance. A-D, data are one representative experiment (7-8 mice per group) of 3 independent experiments using 5 to 10 mice per group. Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001.
after a second injection. In the initial studies, low doses of aGC (200 ng injected intraperitoneally) could induce iNKTcell unresponsiveness up to 1 month after injection. In our study, 100 ng of soluble aGC injected i.v. induced a remarkable unresponsiveness of iNKT cells 2 weeks after injection whereas exosomes maintained their ability to stimulate cytokine responses. This is important for the ensuing adaptive immunity because our data show that the OVA-specific CD8 þ T-cell response persists after 2 injections of Exo(aGC-OVA), but not of soluble aGC and OVA.
To test whether this lack of anergy induction had a functional relevance for the induction of antitumor immunity, we evaluated the therapeutic effect of Exo(aGC-OVA) treatment in an OVA-expressing melanoma model. We observed additive treatment effects with two injections of Exo(aGC-OVA), suggesting that exosomal delivery might allow for multiple boost injections of aGC during a treatment regimen. Based on the results of this study, we speculate that the codelivery of lipid and a protein antigen is beneficial to induce adaptive antitumor immunity.
In summary, we present novel data stating that aGC-loaded exosomes boost innate and antigen-specific Th1 adaptive immunity and enhance antitumor immunity without inducing iNKT-cell anergy. Our approach increased the immunogenicity of dendritic cell-derived exosomes and should be taken into account when designing future clinical therapies for malignant diseases.
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